Evidence map›Paper›PMID 41257706›Full record

ReviewBMC neurology2025

Tumefactive demyelinating lesions: a case report and literature review.

Raneem Jaki, Zyad Al-Frejat, Ziad Bitar

Abstract readCase ReportsReview
In one paragraph

Review in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Tumefactive demyelinating disorders as neoplasm mimics: description of a typical case and literature review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Raneem JakiDepartment of neurology, Damascus university, Damascus, Syria.
Zyad Al-FrejatDepartment of Radiology, Damascus University, Damascus, Syria. Zyadfrejat@gmail.com.ORCID http://orcid.org/0000-0002-3885-6803
Ziad BitarProfessor of Neurology, AL-Sham private University, Damascus, Syria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumefactive multiple sclerosis (TMS) is a rare and diagnostically challenging variant of demyelinating disease that frequently mimics neoplastic, infectious, or vascular brain lesions. Its variable presentation often leads to diagnostic uncertainty and delayed treatment. We describe a case of a 46-year-old woman who presented with subacute neurological deficits and a large, contrast-enhancing lesion on MRI, initially suspected to be a high-grade glioma. Cerebrospinal fluid studies and advanced MRI sequences, including diffusion-weighted imaging (DWI), MR spectroscopy (MRS),were inconclusive.Histopathological examination following brain biopsy confirmed the diagnosis of TMS. The patient was treated with high-dose intravenous corticosteroids, followed by plasma exchange for steroid-refractory symptoms, resulting in partial neurological and radiological improvement. This case highlights the diagnostic complexities of TMS, emphasizing the importance of integrating advanced neuroimaging, multidisciplinary clinical assessment, and histopathological confirmation. We review recent literature on the epidemiology, radiological features, immunopathology, and evolving therapeutic approaches to TMS. Advances in MRI techniques and increased clinical awareness have improved detection, but challenges remain, especially in low-resource settings. TMS should be considered in the differential diagnosis of solitary, tumor-like brain lesions, particularly in young adults with prior demyelinating events. Early recognition and collaborative management are essential to avoid unnecessary surgical interventions and optimize patient outcomes.

Indexed as

BrainDemyelinating DiseasesMultiple SclerosisDiagnosis, DifferentialFemaleHumansMagnetic Resonance ImagingMiddle AgedBiopsyMultiple sclerosisPlasma exchangeTumefactiveTumor

Identifiers

PMID41257706
PMCPMC12628849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.